Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective
Lewczuk P, Mroczko B, Fagan A, Kornhuber J (2015)
Publication Type: Journal article
Publication year: 2015
Journal
Book Volume: 60
Pages Range: 76-82
Journal Issue: 1
DOI: 10.1016/j.advms.2014.11.002
Abstract
A growing body of evidence supports the application of the neurochemical dementia diagnostics (NDD) biomarkers for the diagnosis of dementing conditions. Biomarkers of Alzheimer's disease (AD) were recently classified as these reflecting amyloid ? pathology (decreased CSF concentrations of A?42 and/or positive A? PET scan) and these reflecting neurodegeneration (increased CSF Tau concentrations, decreased uptake of FDG on FDG-PET, and cerebral atrophy on structural MRI). Particularly important seems the role of the biomarkers in the early diagnosis of AD, as the first pathophysiologic events observable in the CSF and amyloid ?-PET occur years and perhaps decades before the onset of the earliest clinical symptoms. Therefore, the NDD tools enable the diagnosis of AD already in the early preclinical stage. This review summarizes pathophysiology underlying the CSF biomarkers, following a discussion of their role in the current guidelines for the diagnostic procedures.
Authors with CRIS profile
Piotr Lewczuk
Department of Psychiatry and Psychotherapy
Johannes Kornhuber
Lehrstuhl für Psychiatrie und Psychotherapie
Involved external institutions
United States (USA) (US)
Poland (PL)How to cite
APA:
Lewczuk, P., Mroczko, B., Fagan, A., & Kornhuber, J. (2015). Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. Advances in Medical Sciences, 60(1), 76-82. https://doi.org/10.1016/j.advms.2014.11.002
MLA:
Lewczuk, Piotr, et al. "Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective." Advances in Medical Sciences 60.1 (2015): 76-82.
BibTeX: Download